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Comparative efficacy and tolerability of 32 oral antipsychotics 
for the acute treatment of adults with multi-episode 
schizophrenia: a systematic review and network meta-analysis
Maximilian Huhn, Adriani Nikolakopoulou, Johannes Schneider-Thoma, Marc Krause, Myrto Samara, Natalie Peter, Thomas Arndt, Lio Bäckers, 
Philipp Rothe, Andrea Cipriani, John Davis, Georgia Salanti, Stefan Leucht
Summary
Background Schizophrenia is one of the most common, burdensome, and costly psychiatric disorders in adults 
worldwide. Antipsychotic drugs are its treatment of choice, but there is controversy about which agent should be 
used. We aimed to compare and rank antipsychotics by quantifying information from randomised controlled trials.
Methods We did a network meta-analysis of placebo-controlled and head-to-head randomised controlled trials and 
compared 32 antipsychotics. We searched Embase, MEDLINE, PsycINFO, PubMed, BIOSIS, Cochrane Central 
Register of Controlled Trials (CENTRAL), WHO International Clinical Trials Registry Platform, and ClinicalTrials.gov 
from database inception to Jan 8, 2019. Two authors independently selected studies and extracted data. We included 
randomised controlled trials in adults with acute symptoms of schizophrenia or related disorders. We excluded 
studies in patients with treatment resistance, first episode, predominant negative or depressive symptoms, 
concomitant medical illnesses, and relapse-prevention studies. Our primary outcome was change in overall symptoms 
measured with standardised rating scales. We also extracted data for eight efficacy and eight safety outcomes. 
Differences in the findings of the studies were explored in metaregressions and sensitivity analyses. Effect size 
measures were standardised mean differences, mean differences, or risk ratios with 95% credible intervals (CrIs). 
Confidence in the evidence was assessed using CINeMA (Confidence in Network Meta-Analysis). The study protocol 
is registered with PROSPERO, number CRD42014014919.
Findings We identified 54 417 citations and included 402 studies with data for 53 463 participants. Effect size estimates 
suggested all antipsychotics reduced overall symptoms more than placebo (although not statistically significant for 
six drugs), with standardised mean differences ranging from –0·89 (95% CrI –1·08 to –0·71) for clozapine to –0·03 
(–0·59 to 0·52) for levomepromazine (40 815 participants). Standardised mean differences compared with placebo for 
reduction of positive symptoms (31 179 participants) varied from –0·69 (95% CrI –0·86 to –0·52) for amisulpride to 
–0·17 (–0·31 to –0·04) for brexpiprazole, for negative symptoms (32 015 participants) from –0·62 (–0·84 to –0·39; 
clozapine) to –0·10 (–0·45 to 0·25; flupentixol), for depressive symptoms (19 683 participants) from –0·90 (–1·36 to 
–0·44; sulpiride) to 0·04 (–0·39 to 0·47; flupentixol). Risk ratios compared with placebo for all-cause discontinuation 
(42 672 participants) ranged from 0·52 (0·12 to 0·95; clopenthixol) to 1·15 (0·36 to 1·47; pimozide), for sedation 
(30 770 participants) from 0·92 (0·17 to 2·03; pimozide) to 10·20 (4·72 to 29·41; zuclopenthixol), for use of 
antiparkinson medication (24 911 participants) from 0·46 (0·19 to 0·88; clozapine) to 6·14 (4·81 to 6·55; pimozide). 
Mean differences compared to placebo for weight gain (28 317 participants) ranged from –0·16 kg (–0·73 to 0·40; 
ziprasidone) to 3·21 kg (2·10 to 4·31; zotepine), for prolactin elevation (21 569 participants) from –77·05 ng/mL 
(–120·23 to –33·54; clozapine) to 48·51 ng/mL (43·52 to 53·51; paliperidone) and for QTc prolongation 
(15 467 participants) from –2·21 ms (–4·54 to 0·15; lurasidone) to 23·90 ms (20·56 to 27·33; sertindole). Conclusions 
for the primary outcome did not substantially change after adjusting for possible effect moderators or in sensitivity 
analyses (eg, when excluding placebo-controlled studies). The confidence in evidence was often low or very low.
Interpretation There are some efficacy differences between antipsychotics, but most of them are gradual rather than 
discrete. Differences in side-effects are more marked. These findings will aid clinicians in balancing risks versus 
benefits of those drugs available in their countries. They should consider the importance of each outcome, the 
patients’ medical problems, and preferences.
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Introduction
Schizophrenia is a common debilitating disorder (1% of 
the world population are afflicted) with a huge burden 
for patients, which cost the USA US$155·7 billion in 
2013.1,2 Antipsychotics are the mainstay of treatment,3 
but are associated with important side-effects that can 
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cause serious disability or death.4 According to WHO,5 
many drugs are available that vary considerably in their 
affinity to different synaptic receptors, leading to possible 
diverging efficacy and safety profiles. Many guidelines 
recommend newer antipsychotics as the treatment of 
choice, but older antipsychotics are less costly and are 
still used worldwide, especially in low-income countries.6 
Moreover, neither these older anti psychotics nor the 
more recently approved brexpiprazole and cariprazine 
have been compared in a comprehensive network meta-
analysis.7 A clear understanding of the relative risks 
and benefits is essential for informed decision making. 
This systematic review and meta-analysis extends 
our previous work3 that combined evidence from 
212 randomised trials on 15 antipsychotics and seven 
outcomes to 402 randomised trials on 32 antipsychotics 
and placebo and 17 efficacy and safety outcomes, with 
change in overall symptoms as the primary outcome. We 
aimed to better inform clinical practice and mental 
health policies by comparing all licensed second-
generation and 17 first-generation antipsychotics in the 
acute treatment of adults with schizophrenia.
Methods
Search strategy and selection criteria
We did a systematic review and network meta-analysis of 
placebo-controlled and head-to-head randomised con-
trolled trials (RCTs) according to PRISMA guidelines.8 We 
included RCTs in adults with acute symptoms of schizo-
phrenia or related disorders (such as schizo phreniform 
or schizoaffective disorders). We excluded studies in 
patients with treatment resis tance, first episode, pre-
domi nant negative or depressive symptoms, concomitant 
medical illnesses, and relapse-prevention studies.
We included all second-generation (atypical) anti-
psychotics available in Europe or the USA, placebo and a 
selection of first-generation (typical or conventional) 
antipsychotics (benperidol, chlorpromazine, clopen thixol 
[cis-isomer and trans-isomer], flupentixol, fluphenazine, 
haloperidol, levomepromazine, loxapine, molindone, 
penfluridol, perazine, perphenazine, pimozide, sulpiride, 
thioridazine, thiotixene, trifluoperazine, and zuclo-
penthixol [cis-isomer]) guided by a survey of 50 interna-
tional schizophrenia experts.9 We excluded intramuscular 
formulations because they are primarily used for relapse 
Research in context
Evidence before this study
Treatment with antipsychotic drugs is the standard for the acute 
phase of schizophrenia according to most national and 
international guidelines. Nevertheless, antipsychotic use is 
debated strongly owing to side-effects and possible brain 
changes. Because many antipsychotic drugs are available, 
according to WHO, understanding how the many substances 
compare with each other is important, ideally ranked in a 
hierarchy. Due to their diverging receptor binding profiles, 
different antipsychotics can vary considerably in their efficacy 
and side-effect profiles. Even with a large evidence base of 
randomised clinical trials for acute treatment of schizophrenia, 
many evidence gaps remain, because many substances have 
never been compared directly in trials, especially older 
antipsychotics. We searched PubMed for network meta-analyses 
on the acute treatment of schizophrenic patients with 
antipsychotics published between database inception and 
Oct 5, 2018. Using the search terms “antipsychotic” AND 
“schizophrenia” AND (“network meta-analysis” OR “multiple 
treatment meta-analysis”), we found several relevant systematic 
reviews. Some examined specific subgroups, such as children or 
first-episode patients, whereas others were restricted to specific 
populations, such as Chinese or Japanese people. Some focused 
on special outcomes like weight gain or glucose. One network 
meta-analysis from 2013 did not include the newly approved 
antipsychotics cariprazine and brexpiprazole and examined only 
the two older antipsychotics haloperidol and chlorpromazine. 
Furthermore, not all clinically important efficacy and safety 
outcomes were studied in this report. Altogether we found no 
comprehensive and systematic network meta-analysis 
comparing older and newer antipsychotics for the acute 
treatment of schizophrenia over several efficacy and safety 
outcomes.
Added value of this study
To our knowledge, this analysis is the largest network 
meta-analysis done in the field of schizophrenia. It was based 
on 402 studies including 53 463 participants randomly 
assigned to 32 different older and newer antipsychotics or 
placebo. The addition of two new and 15 old antipsychotics is a 
major extension of a previous report by our group. 
We investigated ten additional important outcomes, such as 
specific aspects of efficacy, quality of life, and many more 
side-effects, and several methodological issues, such as placebo 
response and sample sizes. The primary outcome was reduction 
of overall schizophrenic symptoms, but we also examined other 
domains: reduction in positive and negative symptoms, 
dropouts, depression, quality of life, and functioning. Newer 
and older antipsychotics reduced overall symptoms more than 
placebo and had lower all-cause discontinuation rates than 
placebo. Differences in side-effects between drugs were often 
large. Because smaller amounts of data were available for older 
antipsychotics, comparisons involving them were often more 
uncertain and their evidence of lower quality. Conclusions for 
the primary outcome did not substantially change after 
adjusting for possible effect moderators or in sensitivity 
analyses (eg, when excluding placebo-controlled studies).
Implications of all the available evidence
These findings provide treatment rankings for older and newer 
antipsychotics for 17 different outcomes, which should inform 
the decision making process and clinical guidelines 
internationally.
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prevention (long-acting) or emergency use (short-acting). 
We included all flexible-dose studies because they allow 
the investigators to titrate to optimum dose for the 
individual patient. In fixed-dose studies, we included 
target-to-maximum doses according to the International 
Consensus Study on Antipsychotic Dose.10 If studies used 
several doses, we averaged the results of the individual 
groups using weighted means.11
We included published and unpublished RCTs com-
paring one antipsychotic with another or with placebo. 
Trials in which antipsychotics were used as an aug-
mentation or combination strategy were excluded. For 
subjective outcomes (eg, overall change in sym ptoms), 
we included only double-blind studies, because an 
absence of blinding can exaggerate differences between 
treatments in this area.12 For objective outcomes, open 
studies were included (appendix pp 271, 272). We 
included short-term studies with a follow-up period of 
3–13 weeks.13 Studies with a high risk of bias in sequence 
generation or allocation concealment according to the 
Cochrane Collaboration’s risk of bias tool were 
excluded.11 We a-priori excluded studies from mainland 
China owing to quality concerns.14 We searched 
MEDLINE, Cochrane Central Register of Controlled 
Trials (CENTRAL), Embase, Biosis, PsycINFO, PubMed, 
ClinicalTrials.gov, WHO International Clinical Trials 
Registry Platform and the US Food and Drug 
Administration website without language restrictions 
from database inception until Jan 8, 2019. The search 
strategy combined terms for schizophrenia or psychosis 
and various drug names (appendix pp 25–48). Reference 
lists of the included studies and previous reviews were 
screened for additional studies.
At least two reviewers (MH, MK, MS, and Yikang Zhu 
[Shanghai Mental Health Center]) screened the search 
results independently, retrieved full-text articles, and 
checked inclusion criteria. In case of doubt a third 
reviewer (SL) was involved. Two reviewers indepen -
dently extracted data and entered them in electronic 
forms in Microsoft Access 2010 (MH, JS-T, MK, MS, 
NP, TA, LB, PR, Yikang Zhu, Matteo Rabaioli-Fischer, 
Susanne Bächer, Leonie Reichelt, and Hannah Röder 
[Technical University of Munich]). An algorithm 
checked for conflicting data entries. Differences were 
discussed, and a third reviewer (SL) was contacted 
if consensus was not reached. Study authors were 
contacted in case of missing or unclear information. For 
dichotomous data we assumed that participants lost to 
follow-up would not have responded. Missing standard 
deviations were estimated from test statistics or by 
using the mean standard deviation of the remaining 
studies.15 Risk of bias in RCTs for the primary outcome 
was assessed independently using the Cochrane Collab-
oration’s risk of bias tool (appendix pp 273–77).11 The 
overall risk of bias was classified into high, moderate, or 
low as proposed in a large network meta-analysis for 
anti depressants.16
Outcomes
The primary outcome was change in overall symptoms of 
schizophrenia as measured by rating scales, such as the 
Positive and Negative Syndrome Scale, the Brief 
Psychiatric Rating Scale, or any other published scale.17 
Secondary outcomes were all-cause discontinuation, 
discontinuation due to inefficacy and responder rates 
(study defined), as well as change in positive, negative, 
and depressive symptoms, quality of life, and social 
functioning, measured by means of published rating 
scales. The following major side effects were examined: 
use of antiparkinson drugs as a measure of extrapyramidal 
side-effects, akathisia, weight gain in kg, 7% weight gain 
or more, prolactin levels, sedation or somnolence, QTc 
prolongation, and at least one anticholinergic side-effect 
(appendix pp 271, 272).
Data analysis
We did a network meta-analysis combining direct and 
indirect comparisons in a Bayesian hierarchical model 
using the rjags package (appendix pp 49–52).18 Effect 
sizes were risk ratios for dichotomous outcomes and 
standardised mean differences (SMDs) for efficacy related 
continuous outcomes, because different rating scales 
were used. Mean differences were applied for weight 
gain, QTc pro longation, and prolactin elevation for 
clinically palpable results. Data were combined using a 
random-effects model. Treatments were ranked using the 
surface under the curve cumulative ranking probabilities. 
The transitivity assumption was evaluated by comparing 
ClozapineFlupentixol Clopenthixol
Chlorpromazine
Cariprazine
Brexpiprazole
Asenapine
Aripiprazole
Amisulpride
Zuclopenthixol
Zotepine
Ziprasidone
Trifluoperazine
Thiotixene
Thioridazine
Sulpiride
Sertindole
RisperidoneQuetiapine
Placebo
Pimozide
Perphenazine
Perazine
Penfluridol
Paliperidone
Olanzapine
Molindone
Lurasidone
Loxapine
Iloperidone
Haloperidol
Fluphenazine
Levomepromazine
Figure 1: Network plot of overall efficacy
The size of the nodes corresponds to the number of participants assigned to each treatment. Treatments with direct 
comparisons are linked with a line; its thickness corresponds to the number of trials evaluating the comparison.
See Online for appendix
Articles
942 www.thelancet.com   Vol 394   September 14, 2019
High Moderate Low Very low
–0·62 (–0·84 to –0·39)
–0·54 (–0·77 to –0·31)
–0·50 (–0·64 to –0·37)
–0·45 (–0·51 to –0·39)
–0·42 (–0·55 to –0·29)
–0·42 (–0·59 to –0·25)
–0·37 (–0·43 to –0·31)
–0·37 (–0·47 to –0·28)
–0·37 (–0·48 to –0·25)
–0·35 (–0·51 to –0·18)
–0·33 (–0·43 to –0·23)
–0·33 (–0·41 to –0·24)
–0·32 (–0·44 to –0·20)
–0·31 (–0·38 to –0·24)
–0·29 (–0·39 to –0·18)
–0·29 (–0·35 to –0·23)
–0·17 (–0·59 to 0·23)
–0·25 (–0·36 to –0·14)
–0·09 (–0·57 to 0·40)
–0·22 (–0·33 to –0·11)
–0·10 (–0·45 to 0·25) 
0·00 (0·00 to 0·00)
CLO (n=159)
ZOT (n=149)
AMI (n=691)
OLA (n=4224)
ASE (n=733)
PERPH (n=311)
RIS (n=3435)
PAL (n=1373)
SER (n=864)
CPZ (n=420)
ZIP (n=959)
ARI (n=1353)
CAR (n=999)
QUE (n=2994)
LUR (n=1165)
HAL (n=3331)
ZUC (n=50)
BRE (n=1180)
LEV (n=21)
ILO (n=918)
FPX (n=73)
PBO (n=6613)
–0·89 (–1·08 to –0·71)
–0·73 (–0·89 to –0·58)
–0·61 (–0·82 to –0·40)
–0·63 (–0·97 to –0·30)
–0·56 (–0·62 to –0·50)
–0·55 (–0·62 to –0·48)
–0·56 (–0·75 to –0·38)
–0·54 (–0·82 to –0·27)
–0·51 (–0·75 to –0·27)
–0·49 (–0·59 to –0·38)
–0·47 (–0·53 to –0·41)
–0·48 (–0·87 to –0·09)
–0·45 (–0·63 to –0·26)
–0·44 (–0·57 to –0·31)
–0·43 (–0·77 to –0·08)
–0·42 (–0·78 to –0·06)
–0·42 (–0·78 to –0·04)
–0·39 (–1·13 to 0·36)
–0·42 (–0·50 to –0·33)
–0·41 (–0·50 to –0·32)
–0·41 (–0·52 to –0·30)
–0·40 (–0·54 to –0·26)
–0·39 (–0·52 to –0·26)
–0·36 (–0·48 to –0·24)
–0·30 (–0·75 to 0·14)
–0·29 (–0·72 to 0·14)
–0·34 (–0·49 to –0·20)
–0·33 (–0·44 to –0·22)
–0·24 (–0·62 to 0·13)
–0·24 (–0·53 to 0·05)
–0·26 (–0·39 to –0·12)
–0·03 (–0·59 to 0·52)
0·00 (0·00 to 0·00)
CLO (n=270)
AMI (n=705)
ZOT (n=245)
THIOT (n=71)
OLA (n=5602)
RIS (n=3827)
PERPH (n=378)
THIOR (n=121)
ZUC (n=178)
PAL (n=1584)
HAL (n=4400)
SUL (n=66)
LOX (n=289)
CPZ (n=741)
FPX (n=88)
CPX (n=60)
MOL (n=67)
PEN (n=14)
QUE (n=3002)
ARI (n=1926)
ZIP (n=1228)
SER (n=868)
ASE (n=1027)
LUR (n=1363)
PIM (n=44)
PERA (n=51)
CAR (n=999)
ILO (n=2157)
FLU (n=53) 
TRIFLU (n=123)
BRE (n=1180)
LEV (n=21)
PBO (n=8067)
SMD (95% CrI)
A Overall change in symptoms (NT=218 [54%], nT=40815 [76%])
SMD (95% CrI)
C Negative symptoms (NT=132 [33%], nt=32015 [60%])
Favours antipsychotic Favours placebo
0–0·5 1·5–1·0 1·00·5
–0·90 (–1·36 to –0·44)
–0·52 (–0·82 to –0·23)
–0·44 (–0·60 to –0·28)
–0·37 (–0·46 to –0·29)
–0·40 (–0·69 to –0·10)
–0·36 (–0·63 to –0·09)
–0·33 (–0·44 to –0·21)
–0·32 (–0·47 to –0·17)
–0·26 (–0·76 to 0·23)
–0·26 (–1·05 to 0·54)
–0·24 (–0·34 to –0·13)
–0·23 (–0·34 to –0·11)
–0·22 (–0·66 to 0·21)
–0·20 (–0·87 to 0·46)
–0·21 (–0·36 to –0·06)
–0·18 (–0·94 to 0·60)
–0·20 (–0·32 to –0·09)
–0·17 (–0·66 to 0·31)
–0·17 (–0·61 to 0·27)
–0·16 (–0·53 to 0·20)
–0·18 (–0·37 to 0·03)
–0·17 (–0·26 to –0·08)
–0·16 (–0·29 to –0·03)
–0·06 (–0·69 to 0·58)
–0·12 (–0·41 to 0·17)
–0·06 (–0·66 to 0·54)
–0·11 (–0·29 to 0·07) 
0·04 (–0·39 to 0·47) 
0·00 (0·00 to 0·00)
SUL (n=52)
CLO (n=108)
AMI (n=663) 
OLA (n=2753) 
ARI (n=150) 
CAR (n=305) 
PAL (n=1267) 
ASE (n=676) 
ZOT (n=88) 
PERA (n=20) 
QUE (n=1996) 
RIS (n=1566) 
PERPH (n=51) 
PIM (n=20) 
ZIP (n=567) 
PEN (n=14) 
LUR (n=1247)
THIOT (n=70)
TRIFLU (n=41)
ZUC (n=70) 
CPZ (n=452) 
HAL (n=1922) 
BRE (n=1090) 
MOL (n=15) 
LOX (n=133) 
CPX (n=15) 
SER (n=447) 
FPX (n=62) 
PBO (n=4823)
–0·69 (–0·86 to –0·52)
–0·61 (–0·68 to –0·54)
–0·64 (–1·09 to –0·19)
–0·53 (–0·60 to –0·46)
–0·53 (–0·65 to –0·42)
–0·57 (–0·88 to –0·25)
–0·49 (–0·56 to –0·41)
–0·47 (–0·63 to –0·32)
–0·45 (–0·66 to –0·24)
–0·43 (–0·89 to 0·03)
–0·43 (–0·53 to –0·32)
–0·40 (–0·54 to –0·27)
–0·40 (–0·49 to –0·31)
–0·38 (–0·77 to 0·01)
–0·38 (–0·48 to –0·28)
–0·33 (–0·45 to –0·20)
–0·30 (–0·45 to –0·16)
–0·21 (–0·72 to 0·31)
–0·30 (–0·43 to –0·17)
–0·18 (–0·75 to 0·39)
–0·17 (–0·31 to –0·04) 
0·00 (0·00 to 0·00)
AMI (n=626)
RIS (n=3351)
CLO (n=31)
OLA (n=4227)
PAL (n=1373)
CPZ (n=190)
HAL (n=3042)
ASE (n=734)
PERPH (n=311)
ZUC (n=50)
ZIP (n=1102)
SER (n=876)
QUE (n=2935)
FPX (n=73)
ARI (n=1451)
LUR (n=1165)
CAR (n=999)
ZOT (n=35)
ILO (n=918)
LEV (n=21)
BRE (n=1180)
PBO (n=6489)
SMD (95% CrI)
B Positive symptoms (NT=117 [29%], nt=31179 [58%])
SMD (95% CrI)
D Depressive symptoms (NT=89 [22%], nt=19683 [37%])
Favours antipsychotic Favours placebo
0–0·5 1·5–1·0 1·00·5
(Figure 2 continues on next page)
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the distribution of potential effect modifiers (placebo 
response, publication year, sample size, baseline severity, 
mean age, and percentage male) across studies grouped 
by comparison (appendix pp 54–61). We assumed a 
common heterogeneity parameter across the various 
treatment comparisons and presented the between-study 
variance τ² for each outcome. We characterised the 
amount of heterogeneity as low, moderate, or high using 
the first and third quantiles of their empirical 
distributions.19 We evaluated consistency statistically (the 
agreement of the various sources of evidence) using the 
design-by-treatment test20 and by separating indirect from 
direct evidence (SIDE test)21 using the R netmeta package 
(appendix pp 223, 224).22 We explored residual 
heterogeneity and inconsistency by several a-priori 
defined metaregressions (with covari ates: placebo 
response rate, study sample size, study publication year, 
baseline severity, sponsor ship, mean age, and percentage 
male) and sensitivity analyses (excluding studies at 
overall high risk of bias, that did a completer analysis, 
with imputed standard deviations, that were placebo-
controlled, with duration more than 6 weeks, that were 
published before 1990, that were considered failed trials, 
and with unfair dose comparison, and excluding placebo 
arms; appendix pp 49–52, 268–70). We used contour-
enhanced funnel plots and the trim-and-fill method for 
the primary outcome to investigate the presence of small-
study effects, whereby small studies give different results 
from the large studies for all comparisons against placebo 
and against haloperidol.23,24
The certainty of evidence produced by the synthesis for 
each outcome was evaluated using the framework de-
scribed by Salanti and colleagues25 and implemented 
using the CINeMA (Confidence in Network Meta-
Analysis) web application which allows confidence in the 
results to be graded as high, moderate, low, and very low 
(appendix pp 238–67).26 For the primary outcome we 
examined the confidence of evidence of all comparisons. 
For the remaining outcomes we examined the com-
parisons of antipsychotics versus placebo. The protocol is 
registered with PROSPERO, number CRD42014014919 
(appendix pp 8–24).
Role of the funding source
The funder of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
Figure 2: Change in efficacy outcomes
(A) Overall change in symptoms. (B) Positive symptoms. (C) Negative symptoms. 
(D) Depressive symptoms. (E) Social functioning. (F) All-cause discontinuation. 
Treatments are ranked according to their surface under the curve cumulative ranking 
and compared with placebo. Effect sizes are presented as standardised mean 
difference or risk ratio with 95% CrIs. The evidence is graded using the CINeMA 
system (Confidence in Network Meta-Analysis), an adaption of the GRADE (Grading 
of Recommendations, Assessment, Development, and Evaluations) approach for 
network meta-analysis. Colours indicate the confidence in the evidence: 
green=high, blue=moderate, grey=low, red=very low. NT=total number of trials 
reporting the outcome (percentage of sample). nT=total number of participants 
available for the respective outcome (percentage of sample). SMD=standardised 
mean difference. CrI=credible interval. RR=risk ratio. AMI=amisulpride. 
ARI=aripiprazole. ASE=asenapine. BRE=brexpiprazole. CAR=cariprazine. 
CLO=clozapine. CPX=clopenthixol. CPZ=chlorpromazine. FLU=fluphenazine. 
FPX=flupentixol. HAL=haloperidol. ILO=iloperidone. LEV=levomepromazine. 
LOX=loxapine. LUR=lurasidone. MOL=molindone. OLA=olanzapine. 
PAL=paliperidone. PBO=placebo. PEN=penfluridol. PERA=perazine. 
PERPH=perphenazine. PIM=pimozide. QUE=quetiapine. RIS=risperidone. 
SER=sertindole. SUL=sulpiride. THIOR=thioridazine. THIOT=thiotixene. 
TRIFLU=trifluoperazine. ZIP=ziprasidone. ZOT=zotepine. ZUC=zuclopenthixol.
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Results
The search identified 54 417 citations, including 
22 074 unique reports, and 2827 full-text articles were 
retrieved after the exclusion of 19 247 reports on the 
NA NA
–0·49 
(–0·74 to 
–0·24)  
–0·38 
(–0·78 to 
0·01)
–0·74 
(–1·19 to 
–0·28)
–0·06 
(–0·19 to 
0·08)
–0·15 
(–0·60 
to 0·31)
0·08 
(–0·58 
to 0·75)
 0·01 
(–0·17 to 
0·20)
 0·00 
(–0·19 to 
0·20)
–0·07 
(–0·45 to 
0·32)
–0·05 
(–0·31 to 
0·23)
–0·17 
(–0·40 
to 0·06)
–0·19 
(–0·50 to 
0·12)
–0·22 
(–0·50 to 
0·05)
–0·07 
(–0·40 
to 0·28)
–0·09 
(–0·47 to 
0·29)
–0·02 
(–0·29 to 
0·27)
–0·01 
(–0·29 to 
0·27)
–0·02 
(–0·36 
to 0·31)
–0·33 
(–0·58 
to –0·07)
–0·35 
(–0·67 to 
–0·02)
–0·38 
(–0·68 to 
–0·09)
–0·41 
(–0·62 to 
–0·20)
–0·42 
(–0·60 to 
–0·24)
–0·25 
(–0·43 to 
–0·07)
–0·26 
(–0·41 to 
–0·12)
–0·02 
(–0·28 
to 0·23)
–0·12 
(–0·35 to 
0·11)
–0·14 
(–0·34 to 
0·07)
–0·15 
(–0·50 to 
0·21)
–0·16 
(–0·51 to 
0·18)
–0·07 
(–0·18 to 
0·04)
–0·09 
(–0·16 to 
–0·01)
–0·06 
(–0·19 to 
0·06)
–0·08 
(–0·15 to 
0·00)
–0·08 
(–0·29 to 
0·14)
–0·06 
(–0·36 
to 0·24)
–0·04 
(–0·28 
to 0·20)
–0·09 
(–0·28 
to 0·10
–0·07 
(–0·35 to 
0·21)
–0·02 
(–0·14 to 
0·11)
 0·00 
(–0·41 to 
0·40)
 0·00 
(–0·41 to 
0·40)
–0·02 
(–0·21 to 
0·17)
–0·04 
(–0·44 
to 0·37)
–0·04 
(–0·42 to 
0·35)
  0·00 
(–0·20 to 
0·19)
–0·02 
(–0·41 to 
0·36)
–0·02 
(–0·38 to 
0·35)
–0·02 
(–0·38 to 
0·34)
0·00 
(–0·50 to 
0·49)
–0·01 
(–0·52 to 
0·49)
–0·01 
(–0·50 to 
0·49)
–0·03 
(–0·85 
to 0·78)
–0·03 
(–0·86 
to 0·79)
 0·00 
(–0·37 to 
0·38)
0·03 
(–0·72 to 
0·78)
0·02 
(–0·73 to 
0·77)
–0·01 
(–0·13 to 
0·12)
–0·01 
(–0·13 to 
0·13)
 0·00 
(–0·13 to 
0·13)
–0·01 
(–0·18 to 
0·15)
–0·01 
(–0·18 to 
0·15)
–0·02 
(–0·19 to 
0·14)
–0·01 
(–0·20 to 
0·18)
–0·03 
(–0·22 to 
0·15)
–0·03 
(–0·20 to 
0·15)
–0·09 
(–0·55 to 
0·37)
–0·06 
(–0·52 to 
0·40)
–0·07 
(–0·52 to 
0·37)
–0·01 
(–0·63 
to 0·60)
0·04 
(–0·43 to 
0·51)
0·05 
(–0·40 
to 0·51)
0·04 
(–0·41 to 
0·48)
–0·02 
(–0·20 to 
0·16)
–0·10
 (–0·50 
to 0·31)
–0·09 
(–0·48 
to 0·30)
–0·09 
(–0·39 to 
0·22)
 0·00 
(–0·46 
to 0·46)
0·01 
(–0·39 to 
0·41)
0·01 
(–0·30 to 
0·33)
–0·21 
(–0·83 to 
0·41)
–0·22 
(–0·79 to 
0·35)
–0·03 
(–0·59 
to 0·52)
–0·26 
(–0·39 to 
–0·12)
–0·24 
(–0·53 to 
0·05)
–0·21 
(–0·88 
to 0·46)
–0·24 
(–0·62 
to 0·13)
–0·07 
(–0·25 to 
0·10)
 –0·30 
(–0·85 
to 0·27)
–0·33 
(–0·44 to 
–0·22)
–0·10 
(–0·43 to 
0·21)
–0·09 
(–0·29 to 
0·11)
–0·31 
(–0·88 
to 0·26)
–0·34 
(–0·49 to 
–0·20)
–0·05 
(–0·62 
to 0·52)
–0·05 
(–0·57 to 
0·46)
–0·04 
(–0·49 
to 0·42)
–0·26 
(–0·96 
to 0·44)
–0·29 
(–0·72 to 
0·14)
0·03 
(–0·43 to 
0·48)
–0·06 
(–0·57 to 
0·45)
–0·06 
(–0·58 
to 0·46)
–0·05 
(–0·50 to 
0·41)
–0·27 
(–0·98 
to 0·43)
–0·30 
(–0·75 to 
0·14)
–0·02 
(–0·21 to 
0·17)
–0·03 
(–0·20 to 
0·13)
–0·12 
(–0·52 to 
0·28)
–0·12 
(–0·44 
to 0·19)
–0·11 
(–0·29 to 
0·07)
–0·33 
(–0·89 
to 0·23)
–0·36 
(–0·48 to 
–0·24)
–0·10 
(–0·55 to 
0·35)
–0·04 
(–0·23 to 
0·15)
–0·06 
(–0·23 to 
0·11)
–0·15 
(–0·54 to 
0·25)
–0·15 
(–0·46 
to 0·17)
–0·13 
(–0·32 to 
0·05)
–0·36 
(–0·92 to 
0·21)
–0·39 
(–0·52 to 
–0·26)
–0·09 
(–0·55 to 
0·36)
–0·10 
(–0·56 
to 0·35)
–0·05 
(–0·25 to 
0·15)
–0·07 
(–0·24 to 
0·11)
–0·15 
(–0·55 to 
0·25)
–0·15 
(–0·47 to 
0·16)
–0·14 
(–0·34 to 
0·05)
–0·36 
(–0·93 to 
0·21)
 –0·40 
(–0·54 to 
–0·26)
–0·05 
(–0·21 to 
0·11)
–0·11 
(–0·56 
to 0·34)
–0·12 
(–0·56 
to 0·33)
–0·07 
(–0·24 to 
0·11)
–0·08 
(–0·23 to 
0·06)
–0·17 
(–0·55 to 
0·22)
–0·17 
(–0·47 to 
0·13)
–0·15 
(–0·33 to 
0·02)
–0·38 
(–0·93 to 
0·19)
–0·41 
(–0·52 to 
–0·30)
–0·02 
(–0·18 to 
0·14)
–0·05 
(–0·20 to 
0·11)
–0·11 
(–0·55 to 
0·34)
–0·12 
(–0·56 
to 0·32)
–0·07 
(–0·23 to 
0·10)
–0·08 
(–0·22 to 
0·06)
–0·17 
(–0·55 to 
0·22)
–0·17 
(–0·47 to 
0·13)
–0·15 
(–0·32 to 
0·01)
–0·38 
(–0·93 to 
0·18)
–0·41 
(–0·50 to 
–0·32)
–0·02 
(–0·18 to 
0·14)
–0·03 
(–0·18 to 
0·12)
–0·05 
(–0·20 to 
0·09)
–0·11 
(–0·56 
to 0·33)
–0·12 
(–0·56 
to 0·31)
–0·07 
(–0·24 to 
0·10)
–0·09 
(–0·22 to 
0·05)
–0·17 
(–0·55 to 
0·21)
–0·17 
(–0·47 to 
0·12)
 –0·16
(–0·32 to 
0·00
–0·38 
(–0·94 
to 0·18)
–0·42 
(–0·50 to 
–0·33)
0·02 
(–0·73 to 
0·77)
0·01 
(–0·75 to 
0·77)
 0·00
 (–0·75 
to 0·75)
–0·02 
(–0·78 to 
0·73)
–0·09 
(–0·94 
to 0·77)
 –0·10 
(–0·95 
to 0·76)
 –0·04 
(–0·80 
to 0·72)
–0·06 
(–0·81 to 
0·69)
–0·14 
(–0·98 
to 0·69)
–0·14 
(–0·95 
to 0·65)
–0·13 
(–0·89 
to 0·63)
–0·35 
(–1·28 to 
0·57)
–0·39 
(–1·13 to 
0·36)
–0·01 
(–0·38 to 
0·37)
–0·01 
(–0·39 to 
0·38)
–0·02 
(–0·41 to 
0·37)
–0·03 
(–0·41 to 
0·36)
–0·05 
(–0·44 
to 0·34)
–0·11 
(–0·68 
to 0·46)
–0·13 
(–0·69 
to 0·44)
–0·07 
(–0·46 
to 0·33)
–0·09 
(–0·46 
to 0·30)
–0·17 
(–0·69 
to 0·35)
–0·17 
(–0·55 to 
0·20)
–0·16 
(–0·55 to 
0·23)
–0·38 
(–1·04 to 
0·27)
–0·42 
(–0·78 to 
–0·04)
–0·01 
(–0·37 to 
0·36)
–0·01 
(–0·38 to 
0·36)
–0·01 
(–0·37 to 
0·36)
–0·03 
(–0·40 
to 0·36)
–0·03 
(–0·41 to 
0·35)
–0·06 
(–0·43 to 
0·32)
–0·12 
(–0·67 to 
0·44)
–0·13 
(–0·68 
to 0·42)
–0·08 
(–0·46 
to 0·31)
–0·09 
(–0·46 
to 0·28)
–0·18 
(–0·68 
to 0·33)
–0·18 
(–0·63 
to 0·26)
–0·17 
(–0·55 to 
0·22)
–0·39 
(–1·04 to 
0·27)
–0·42 
(–0·78 to 
–0·06)
–0·04 
(–0·86 
to 0·79)
–0·01 
(–0·36 
to 0·34)
–0·02 
(–0·37 to 
0·34)
–0·02 
(–0·37 to 
0·34)
–0·03 
(–0·40 
to 0·34)
–0·04 
(–0·41 to 
0·33)
–0·06 
(–0·43 to 
0·30)
–0·12 
(–0·67 to 
0·43)
–0·13 
(–0·67 to 
0·41)
–0·08 
(–0·46 
to 0·29)
 –0·10 
(–0·46 
to 0·26)
–0·18 
(–0·69 
to 0·33)
–0·18 
(–0·63 
to 0·27)
–0·17 
(–0·54 to 
0·20)
–0·39 
(–1·05 to 
0·26)
–0·43 
(–0·77 to 
–0·08)
–0·03 
(–0·39 to 
0·33)
–0·06 
(–0·79 to 
0·68)
–0·03 
(–0·16 to 
0·12)
–0·03 
(–0·19 to 
0·13)
–0·03 
(–0·20 to 
0·13)
–0·05 
(–0·23 to 
0·14)
–0·05 
(–0·23 to 
0·13)
–0·08 
(–0·26 
to 0·10)
–0·14 
(–0·58 
to 0·30)
–0·15 
(–0·60 
to 0·30)
–0·10 
(–0·29 to 
0·10)
–0·11 
(–0·28 
to 0·06)
 –0·20 
(–0·58 
to 0·19)
 –0·20 
(–0·49 
to 0·09)
 –0·19 
(–0·37 
to 0·00
–0·41 
(–0·97 to 
0·16)
–0·44 
(–0·58 to 
–0·31)
–0·03 
(–0·42 to 
0·37)
–0·03 
(–0·42 to 
0·35)
–0·06 
(–0·82 
to 0·71)
–0·03 
(–0·23 to 
0·17)
–0·04 
(–0·24 to 
0·17)
–0·04 
(–0·25 to 
0·17)
–0·05 
(–0·28 
to 0·18)
–0·06 
(–0·28 
to 0·17)
–0·08 
(–0·30 to 
0·13) 
–0·15 
(–0·61 to 
0·33)
–0·16 
(–0·63 to 
0·32)
 –0·10 
(–0·34 to 
0·13)
–0·12 
(–0·33 to 
0·09)
 –0·20 
(–0·61 to 
0·20)
–0·21 
(–0·49 to 
0·08)
–0·19 
(–0·42 to 
0·04)
 –0·41 
(–1·00 to 
0·16)
 –0·45 
(–0·63 to 
–0·26)
–0·06 
(–0·57 to 
0·46)
–0·06 
(–0·58 
to 0·46)
–0·07 
(–0·56 
to 0·45)
–0·10 
(–0·92 to 
0·75)
–0·07 
(–0·46 
to 0·33)
–0·07 
(–0·47 to 
0·33)
–0·07 
(–0·47 to 
0·33)
–0·09 
(–0·50 to 
0·33)
–0·09 
(–0·50 to 
0·32)
–0·12 
(–0·52 to 
0·29)
–0·18 
(–0·75 to 
0·40)
–0·19 
(–0·77 to 
0·38)
–0·14 
(–0·55 to 
0·27)
–0·16 
(–0·55 to 
0·25)
–0·24 
(–0·77 to 
0·29)
–0·24 
(–0·66 
to 0·18)
–0·23 
(–0·63 
to 0·19)
–0·45 
(–1·12 to 
0·23)
–0·48 
(–0·87 to 
–0·09)
–0·03 
(–0·17 to 
0·11)
–0·05 
(–0·39 to 
0·30)
–0·05 
(–0·41 to 
0·30)
–0·05 
(–0·43 to 
0·31)
–0·08 
(–0·83 to 
0·67)
–0·05 
(–0·15 to 
0·04)
–0·06 
(–0·17 to 
0·04)
–0·06 
(–0·17 to 
0·05)
–0·08 
(–0·21 to 
0·06)
–0·08 
(–0·22 to 
0·05)
–0·11 
(–0·24 to 
0·02)
–0·17 
(–0·61 to 
0·28)
–0·18 
(–0·61 to 
0·25)
–0·13 
(–0·28 
to 0·03)
–0·14 
(–0·25 to 
–0·03)
–0·23 
(–0·60 
to 0·15)
–0·23 
(–0·52 to 
0·06)
–0·21 
(–0·37 to 
–0·07)
–0·44 
(–0·98 
to 0·11)
–0·47 
(–0·53 to 
–0·41)
–0·04 
(–0·25 to 
0·18)
–0·04 
(–0·21 to 
0·13)
–0·06 
(–0·42 to 
0·30)
–0·06 
(–0·44 
to 0·31)
–0·07 
(–0·46 
to 0·31)
 –0·10 
(–0·86 
to 0·66)
–0·07 
(–0·20 to 
0·07)
–0·08 
(–0·21 to 
0·06)
–0·08 
(–0·22 to 
0·07)
–0·09 
(–0·26 
to 0·08)
 –0·10 
(–0·26 
to 0·07)
–0·12 
(–0·28 
to 0·04)
–0·18 
(–0·64 
to 0·28)
 –0·20 
(–0·64 
to 0·25)
–0·16 
(–0·31 to 
0·00)
–0·14 
(–0·32 to 
0·04)
–0·24 
(–0·55 to 
0·06)
–0·23 
(–0·40 to 
–0·06)
–0·45 
(–1·01 to 
0·11)
–0·49 
(–0·59 to 
–0·38)
–0·24 
(–0·63 
to 0·15)
–0·03 
(–0·48 
to 0·42)
–0·41 
(–0·84 
to 0·01)
–0·45 
(–0·70 to 
–0·19)
–0·45 
(–0·65 to 
–0·25)
–0·47 
(–0·85 to 
–0·08)
–0·47 
(–0·87 to 
–0·08)
–0·48 
(–0·89 
to –0·07)
–0·29 
(–0·49 to 
–0·10)
–0·25 
(–0·67 to 
0·16)
–0·29 
(–0·52 to 
–0·05)
–0·13 
(–0·56 
to 0·31)
–0·16 
(–0·43 to 
0·12)
–0·18 
(–0·53 to 
0·16)
–0·11 
(–0·30 to 
0·08)
–0·10 
(–0·30 to 
0·09)
–0·12 
(–0·38 to 
0·14)
–0·10 
(–0·40 
to 0·21)
–0·15 
(–0·64 
to 0·34)
–0·08 
(–0·47 to 
0·32)
–0·07 
(–0·46 
to 0·32)
–0·08 
(–0·51 to 
0·34)
–0·06 
(–0·48 
to 0·36)
–0·06 
(–0·36 
to 0·23)
–0·07 
(–0·32 to 
0·19)
–0·17 
(–0·40 
to 0·07)
–0·19 
(–0·54 to 
0·16)
–0·12 
(–0·26 
to 0·03)
–0·11 
(–0·25 to 
0·03)
–0·12 
(–0·34 to 
0·10)
–0·10 
(–0·39 to 
0·19)
–0·08 
(–0·50 to 
0·34)
–0·31 
(–0·64 
to 0·02)
–0·18 
(–0·58 
to 0·22)
–0·21 
(–0·69 
to 0·27)
–0·13 
(–0·48 
to 0·21)
–0·12 
(–0·47 to 
0·22)
–0·14 
(–0·52 to 
0·25)
–0·12 
(–0·56 
to 0·32)
–0·09 
(–0·51 to 
0·33)
–0·13 
(–0·49 
to 0·23)
–0·14 
(–0·51 to 
0·23)
–0·12 
(–0·56 
to 0·32)
–0·14 
(–0·50 to 
0·22)
–0·21 
(–0·71 to 
0·29)
–0·19 
(–0·60 
to 0·22)
–0·31 
(–0·70 to 
0·07)
–0·09 
(–0·52 to 
0·34)
–0·22 
(–0·71 to 
0·28)
–0·14 
(–0·52 to 
0·23)
–0·13 
(–0·51 to 
0·24)
–0·15 
(–0·56 
to 0·26)
–0·13 
(–0·58 
to 0·32)
–0·19 
(–0·61 to 
0·22)
–0·32 
(–0·72 to 
0·07)
–0·12 
(–0·90 
to 0·66)
–0·51 
(–1·27 to 
0·26)
–0·35 
(–1·10 to 
0·42)
–0·22 
(–0·99 
to 0·56)
–0·25 
(–1·07 to 
0·58)
–0·17 
(–0·93 to 
0·57)
–0·16 
(–0·91 to 
0·59)
–0·18 
(–0·94 
to 0·59)
–0·16 
(–0·95 
to 0·63)
–0·09 
(–0·34 to 
0·15)
–0·13 
(–0·41 to 
0·16)
–0·15 
(–0·34 to 
0·05)
–0·22 
(–0·56 
to 0·13)
–0·19 
(–0·41 to 
0·03)
–0·48 
(–0·67 to 
–0·28)
–0·48 
(–0·68 to 
–0·28)
–0·48 
(–0·69 to 
–0·28)
–0·50 
(–0·72 to 
–0·28)
–0·50 
(–0·72 to 
–0·29)
–0·53 
(–0·75 to 
–0·31)
–0·59 
(–1·06 to 
–0·12)
–0·60 
(–1·06 to 
–0·14)
–0·55 
(–0·78 to 
–0·32)
–0·57 
(–0·77 to 
–0·36)
–0·41 
(–0·58 to 
–0·22)
–0·65 
(–1·06 to 
–0·24)
–0·49 
(–0·89 to 
–0·09)
–0·65 
(–0·98 to 
–0·32)
–0·64 
(–0·86 to 
–0·41)
–0·86 
(–1·43 to 
–0·28)
–0·89 
(–1·08 to 
–0·71)
–0·73 
(–0·89 to 
–0·58)
–0·61 
(–0·82 to 
–0·40)
–0·55 
(–0·62 to 
–0·48)
–0·56 
(–0·75 to 
–0·38)
–0·54 
(–0·82 to 
–0·27)
–0·63 
(–0·97 to 
–0·30) 
–0·56 
(–0·62 to 
–0·50) 
–0·70 
(–1·27 to 
–0·13)
–0·48 
(–0·68 to 
–0·27)
–0·35 
(–0·60 to 
–0·10)
–0·38 
(–0·74 to 
–0·01)
–0·30 
(–0·45 to 
–0·15)
–0·29 
(–0·45 to 
–0·14)
–0·31 
(–0·54 to 
–0·08)
–0·49 
(–0·82 to 
–0·17)
–0·37 
(–0·71 to 
–0·02)
–0·32 
(–0·61 to 
–0·03)
–0·31 
(–0·60 to 
–0·02)
–0·28 
(–0·51 to 
–0·05)
–0·23 
(–0·35 to 
–0·11)
–0·22 
(–0·34 to 
–0·10)
–0·24 
(–0·45 to 
–0·02)
–0·39 
(–0·59 to 
–0·18)
–0·26 
(–0·51 to 
–0·01)
–0·21 
(–0·37 to 
–0·06)
–0·21 
(–0·36 to 
–0·05)
–0·37 
(–0·56 to 
–0·18)
–0·25 
(–0·48 to 
–0·01)
–0·34 
(–0·54 to 
–0·15)
–0·17 
(–0·30 to 
–0·04)
–0·16 
(–0·30 to 
–0·02)
–0·17 
(–0·40 to 
0·05)
–0·15 
(–0·46 to 
0·15)
–0·32 
(–0·50 to 
–0·15)
–0·32 
(–0·50 to 
–0·15)
–0·34 
(–0·53 to 
–0·14)
–0·16 
(–0·31 to 
–0·02)
–0·15 
(–0·30 to 
–0·01)
–0·15 
(–0·26 to 
–0·03)
–0·14 
(–0·25 to 
–0·03)
–0·32 
(–0·48 to 
–0·15)
–0·14 
(–0·24 to 
–0·04)
–0·15 
(–0·25 to 
–0·05)
–0·14 
(–0·25 to 
–0·03)
–0·13 
(–0·23 to 
–0·04)
 –0·10 
(–0·35 to 
0·15)
 –0·20 
(–0·42 to 
0·03)
–0·22 
(–0·57 to 
0·12)
–0·15 
(–0·36 
to 0·05)
–0·13 
(–0·42 to 
0·16)
 –0·10 
(–0·35 to 
0·16)
–0·13 
(–0·43 to 
0·16)
–0·15 
(–0·36 
to 0·05)
–0·22 
(–0·58 
to 0·13)
 –0·20 
(–0·43 to 
0·03)
–0·11 
(–0·39 to 
0·16)
–0·15 
(–0·45 to 
0·16)
–0·17 
(–0·40 
to 0·06)
–0·24 
(–0·60 
to 0·13)
–0·21 
(–0·46 
to 0·04)
–0·12 
(–0·39 to 
0·15)
–0·22 
(–0·46 
to 0·03)
–0·24 
(–0·61 to 
0·12)
–0·15 
(–0·42 to 
0·12)
–0·20 
(–0·43 to 
0·02)
–0·18 
(–0·48 
to 0·12)
–0·27 
(–0·63 
to 0·09)
–0·20 
(–0·33 to 
–0·06)
–0·19 
(–0·32 to 
–0·05)
–0·21 
(–0·70 to 
0·29)
–0·26 
(–0·74 to 
0·22)
–0·24 
(–0·74 to 
0·28)
–0·33 
(–0·88 
to 0·22)
–0·26 
(–0·70 to 
0·20)
–0·25 
(–0·69 to 
0·20)
–0·31 
(–0·78 to 
0·18)
–0·43 
(–0·89 
to 0·03)
–0·22 
(–0·71 to 
0·27)
–0·32 
(–0·72 to 
0·09)
–0·34 
(–0·89 
to 0·21)
–0·29 
(–0·66 
to 0·08)
–0·27 
(–0·70 to 
0·17)
–0·26 
(–0·69 
to 0·18)
–0·27 
(–0·74 to 
0·20)
–0·25 
(–0·76 to 
0·26)
–0·44 
(–0·88 to 
0·00)
–0·16 
(–0·44 
to 0·11)
–0·20 
(–0·51 to 
0·11)
–0·22 
(–0·45 to 
0·02)
–0·18 
(–0·44 
to 0·08)
–0·22 
(–0·51 to 
0·08)
–0·30 
(–0·66 
to 0·05)
–0·27 
(–0·71 to 
0·17)
–0·30 
(–0·74 to 
0·14)
–0·32 
(–0·74 to 
0·10)
–0·31 
(–0·69 
to 0·07)
–0·32 
(–0·69 
to 0·06)
–0·39 
(–0·89 
to 0·11)
–0·37 
(–0·79 to 
0·06)
–0·27 
(–0·63 
to 0·10)
–0·32 
(–0·66 
to 0·02)
–0·30 
(–0·68 
to 0·08)
–0·39 
(–0·81 to 
0·03)
–0·25 
(–0·53 to 
0·02)
–0·29 
(–0·60 
to 0·02)
–0·48 
(–1·08 to 
0·12)
–0·53 
(–1·08 to 
0·03)
–0·52 
(–1·07 to 
0·04)
–0·53 
(–1·11 to 
0·05)
–0·51 
(–1·13 to 
0·11)
–0·60 
(–1·24 to 
0·05)
–0·58 
(–1·16 to 
0·01)
–0·51 
(–0·75 to 
–0·27)
–0·09 
(–0·23 to 
0·04)
–0·15 
(–0·28 to 
–0·01)
–0·11 
(–0·40 
to 0·17)
–0·15 
(–0·35 to 
0·04)
–0·05 
(–0·26 
to 0·16)
–0·06 
(–0·27 to 
0·16)
–0·08 
(–0·43 to 
0·26)
–0·01 
(–0·09 
to 0·08)
–0·07 
(–0·42 to 
0·27)
–0·33 
(–0·52 to 
–0·15)
–0·34 
(–0·53 to 
–0·16)
–0·18 
(–0·34 to 
–0·03)
–0·18 
(–0·33 to 
–0·02)
0·05 
(–0·19 to 
0·29)
–0·52 
(–1·71 to 
0·68)
–0·59 
(–1·32 to 
0·14)
0·20 
(–0·60 
to 1·01)
–0·21 
(–0·88 
to 0·46)
0·02 
(–0·47 to 
0·51)
–0·38 
(–0·83 to 
0·06)
–0·13 
(–0·42 to 
0·17)
–0·27 
(–0·83 to 
0·28)
0·29 
(–0·54 to 
1·12)
–0·11 
(–0·50 to 
0·27)
–0·10 
(–0·40 
to 0·21)
–0·12 
(–0·54 to 
0·29)
–0·05 
(–0·29 to 
0·19)
–0·04 
(–0·28 
to 0·20)
–0·05 
(–0·34 to 
0·23)
–0·03 
(–0·39 to 
0·33)
0·10 
(–0·72 to 
0·92)
–0·39 
(–1·00 to 
0·22)
0·01 
(–0·75 to 
0·78)
–0·04 
(–0·55 to 
0·48)
–0·08 
(–0·56 
to 0·41)
–0·05 
(–0·82 
to 0·71)
–0·15 
(–0·32 to 
0·02)
–0·20 
(–0·39 to 
–0·01)
–0·06 
(–0·25 to 
0·13)
0·15 
(–0·23 to 
0·53)
0·14 
(–0·29 to 
0·58)
–0·34 
(–0·64 to 
–0·04)
–0·26 
(–0·48 to 
–0·04)
–0·80 
(–1·47 to 
–0·13)
–0·14 
(–0·80 
to 0·51)
–0·43 
(–1·13 to 
0·26)
–0·12 
(–0·72 to 
0·48)
–0·54 
(–1·16 to 
0·08)
–0·40 
(–1·10 to 
0·31)
–0·22 
(–0·90 
to 0·45)
–0·07 
(–0·47 to 
0·33)
–0·12 
(–0·68 
to 0·43)
–0·21 
(–0·54 to 
0·11)
–0·09 
(–0·51 to 
0·33)
–0·16 
(–1·07 to 
0·75)
–0·08 
(–0·23 to 
0·08)
–0·02 
(–0·32 to 
0·29)
–0·12 
(–0·31 to 
0·07)
0·02 
(–0·30 to 
0·35)
–0·16 
(–0·45 to 
0·14)
–0·23 
(–0·54 to 
0·08)
0·14 
(–0·35 to 
0·08)
–0·18 
(–0·50 to 
0·13)
–0·28 
(–0·65 
to 0·09)
0·27 
(–0·49 
to 1·04)
–0·54 
(–1·21 to 
0·13)
–0·18 
(–0·49 
to 0·14)
0·02 
(–0·28 
to 0·32)
–0·53 
(–0·61 to 
–0·44)
–0·56 
(–0·65 to 
–0·46)
–0·85 
(–1·49 to 
–0·21)
–0·68 
(–1·07 to 
–0·29)
–0·50 
(–0·63 to 
–0·37)
–0·51 
(–0·61 to 
–0·42)
–0·67 
(–1·46 to 
0·11)
–0·43 
(–0·55 to 
–0·31)
–0·38 
(–0·57 to 
–0·20)
–0·30 
(–0·44 to 
–0·16)
–0·38 
(–0·51 to 
–0·25)
–0·36 
(–0·58 to 
–0·15)
–0·39 
(–0·52 to 
–0·26)
–0·24 
(–0·40 to 
–0·08)
–0·68 
(–1·54 to 
0·18)
–0·37 
(–0·53 to 
–0·21)
–0·24 
(–0·94 
to 0·45)
–0·25 
(–0·39 to 
–0·11)
–0·96 
(–1·78 to 
–0·13)
–0·75 
(–1·53 to 
0·02)
–0·52 
(–0·73 to 
–0·30)
–0·41 
(–0·69 to 
–0·13)
–0·16 
(–0·38 to 
0·07)
–0·10 
(–0·27 to 
0·08)
–0·07 
(–0·35 to 
0·20)
–0·08 
(–0·36 
to 0·20)
–0·08 
(–0·28 
to 0·12)
0·00 
(–0·24 to 
0·23)
–0·02 
(–0·27 to 
0·24)
–0·08 
(–0·37 to 
0·22)
–0·16 
(–0·50 to 
0·18)
–1·65 
(–2·69  to 
–0·60)  
–0·58 
(–1·42 to 
0·25)  
–0·24 
(–0·73  
to 0·25)  
–0·82 
(–1·28 to 
–0·36)
–0·32 
(–0·77 to 
0·12)
–0·28 
(–0·50 to 
–0·07)
–0·17 
(–0·63 to 
0·28)
–0·08 
(–0·38 to 
0·23)
0·08 
(–0·19 to 
0·36)
–0·13 
(–0·37 to 
0·12)
–0·48
(–0·91 to 
–0·06)  
–0·07
(–0·38  to 
0·52)  
–0·94 
(–1·63 to 
–0·25)
–0·26 
(–0·65 to 
0·13)
–0·10 
(–0·47 to 
0·27)
0·02 
(–0·37 to 
0·43)
NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA
NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA
NA
NA
NA
NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA
NA
NA
NA
NA
NANA
NANA
NA
NA
NA
NA
–0·23 
(–0·98 to 
0·53)
–0·08 
(–0·68 to 
0·52)
–0·15 
(–0·43 to 
0·14)
–0·16 
(–0·39 to 
0·07)
–0·28 
(–0·54 to 
–0·03)
NA
NA NA NA NA NA NA NA NA NA NA NA NANA NA NA NA NA NA NA NA NA NA NA
NA
NA
NA NA
NA
NA
NA
NA
NA NA
NA
NA
NA
NA
NA
NA
NA
NA NA NA NA NA NA NA NA NA
NA
NA
NA
NA
NA
NA
NA NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
ZUC
PERPH
OLA
AMI
ZOT
CLO
THIOR
RIS
THIOT
NA
NA
NA
NA
NA
NA
PAL
HAL
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
SUL
LOX
CPZ
NA
NA
NANA
NA
NANA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NANA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
–0·06 
(–0·30 to 
0·18)
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NANA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
FPX
CPX
MOL
PEN
QUE
ARI
ZIP
SER
ASE
LUR
PIM
PERA
CAR
ILO
FLU
TRIFLU
BRE
LEV
PBO
NA
Articles
www.thelancet.com   Vol 394   September 14, 2019 945
basis of their titles and abstracts. We screened these 
2827 full-text articles and included 550 reports from 
402 studies with 53 463 participants (appendix 
pp 62–154). The sample had the following characteristics: 
mean age was 37·40 years (SD 5·96), 29 949 (56·02%) 
participants were male and 23 514 (43·98%) female, and 
mean illness duration was 11·90 years (SD 5·19; 
appendix pp 282–84). We excluded studies with high risk 
of bias for randomisation and allocation, but methods 
for sequence generation and allocation concealment 
were often not described in detail and, therefore, were 
coded as unclear (appendix pp 155–76). The percentage 
of studies with high, unclear, and low risk of bias for the 
individual items was: 0%, 73·1%, and 26·9% for 
randomisation, 0%, 78·4%, and 21·6% for allocation 
concealment, 10·7%, 38·6%, and 50·7% for blinding of 
patients and personnel, 13·9%, 34·8%, and 51·3% for 
rater blinding, 23·9%, 35·6%, and 40·5% for missing 
outcomes, 27·4%, 20·9%, and 51·7% for selective 
reporting, and 5·7%, 11·9%, and 82·3% for other biases. 
The overall risk of bias was rated as high for 92 (23%) 
studies.
218 (54%) studies with 40 815 (76%) participants 
presented usable results for change in overall symptoms 
(figure 1). 26 (81%) of 32 antipsychotics were associated 
with significant improvement in symptoms compared 
with placebo (figure 2A). The SMDs for drugs associated 
with significant improvement ranged between –0·89 
(95% credible interval [CrI] –1·08 to –0·71) for clozapine 
to –0·26 (–0·39 to –0·12) for brexpiprazole. Clozapine, 
amisulpride, zotepine, olanzapine, and risperidone re-
duced overall symptoms significantly more than many 
other drugs (figure 3). Most differences between the 
remaining drugs were small or very uncertain.
Secondary efficacy outcomes were reported less 
frequently especially for older drugs including clozapine 
(appendix pp 200–21). 117 studies (29%) with 31 179 partici-
pants (58%) presented results usable for reduction of 
positive symptoms (21 antipsychotics). The SMDs for 
the 17 (81%) drugs that significantly reduced positive 
symp toms compared with placebo ranged between –0·69 
(95% CrI –0·86 to –0·52) for amisulpride to –0·17 (–0·31 
to –0·04) for brexpiprazole (figure 2B). Amisulpride, 
risperidone, olanzapine, paliperidone, and haloperidol 
were significantly more effective than many other drugs 
(appendix pp 200–21).
132 studies (33%) with 32 015 (60%) participants 
reported usable results for negative symptoms (21 anti-
psychotics). The SMDs for the 18 (86%) antipsychotics that 
significantly reduced negative symptoms compared with 
placebo ranged between –0·62 (95% CrI –0·84 to –0·39) 
for clozapine to –0·22 (–0·33 to –0·11) for iloperidone 
(figure 2C). Clozapine, amisulpride, olanzapine, and, to a 
lesser extent, zotepine and risperidone reduced negative 
symptoms significantly more than many other drugs. 
Differences between the remaining drugs were uncertain 
(appendix pp 200–21).
89 studies (22%) with 19 683 participants (37%) reported 
usable results for depressive symptoms (28 antipsychotics). 
The SMDs for the 14 (50%) drugs that significantly reduced 
depressive symptoms compared with placebo ranged 
between –0·90 (95% CrI –1·36 to –0·44) for sulpiride 
and –0·16 (–0·29 to –0·03) for brexpiprazole (figure 2D). 
Sulpiride, clozapine, amisulpride, and olanzapine were 
associated with significantly more reduction of depressive 
symptoms compared with many other drugs (appendix 
pp 200–21), but CrIs were wide.
Only ten studies (3%) with 3341 participants (6%) 
reported usable quality-of-life data (eight antipsychotics). 
Because 50% of the network loops were inconsistent, we 
did a pairwise meta-analysis. Compared with placebo, 
five antipsychotics significantly improved quality of life, 
with SMDs ranging from –0·49 (95% CI –0·72 to –0·26) 
for aripiprazole to –0·18 (–0·34 to –0·02) for paliperidone 
(appendix p 222).
16 studies (4%) with 4370 participants (8%) presented 
usable results for social functioning (12 antipsychotics). 
Based on a small number of studies, thioridazine, 
olanzapine, paliperidone, quetiapine, lura sidone, and 
brexpiprazole were associated with signifi cant improve-
ment in social functioning compared with placebo with a 
SMD range from –0·69 (95% CrI –1·24 to –0·14) for 
thioridazine to –0·25 (–0·38 to –0·12) for brexpiprazole 
(figure 2E).
192 studies with 35 115 participants reported study-
defined response rates, using very different cutoffs 
(appendix p 278). 29 (94%) of 31 antipsychotics had 
significantly higher response rates compared with 
placebo, with risk ratios ranging from 2·16 (95% CrI 
1·53–3·55) for thioridazine to 1·11 (1·01–1·19) for 
brexpiprazole (appendix p 278).
226 (56%) studies reported all-cause discontinuation 
rates for 42 672 (80%) participants (32 antipsychotics). 
Risk ratios for the 20 drugs (63%) that significantly 
lowered discontinuation rates compared with placebo 
ranged from 0·52 (95% CrI 0·12–0·95) for clopenthixol 
to 0·90 (0·85–0·95) for haloperidol (figure 2F). When 
Figure 3: Change in overall symptoms league table
Antipsychotics are reported in order of surface under the curve cumulative 
ranking. Results of the network meta-analysis are presented in the left lower half 
and results from pairwise meta-analysis in the upper right half, if available. 
Comparisons between treatments should be read from left to right and the 
estimate is in the cell in common between the column-defining treatment and 
the row-defining treatment. In the left lower half, standard mean differences 
lower than 0 favour the column-defining treatment and in the upper right half, 
those lower than 0 favour the row-defining treatment. Cells in bold print indicate 
significant results. NA=not available. AMI=amisulpride. ARI=aripiprazole. 
ASE=asenapine. BRE=brexpiprazole. CAR=cariprazine. CLO=clozapine. 
CPX=clopenthixol. CPZ=chlorpromazine. FLU=fluphenazine. FPX=flupentixol. 
HAL=haloperidol. ILO=iloperidone. LEV=levomepromazine. LOX=loxapine. 
LUR=lurasidone. MOL=molindone. OLA=olanzapine. PAL=paliperidone. 
PBO=placebo. PEN=penfluridol. PERA=perazine. PERPH=perphenazine. 
PIM=pimozide. QUE=quetiapine. RIS=risperidone. SER=sertindole. SUL=sulpiride. 
THIOR=thioridazine. THIOT=thiotixene. TRIFLU=trifluoperazine. ZIP=ziprasidone. 
ZOT=zotepine. ZUC=zuclopenthixol.
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High Moderate Low Very low
0·17 (0·00 to 1·34) 
0·54 (0·06 to 1·75) 
0·72 (0·45 to 1·23) 
0·73 (0·16 to 1·94) 
0·99 (0·70 to 1·34) 
1·00 (1·00 to 1·00)
1·01 (0·68 to 1·58) 
1·35 (0·80 to 2·08) 
1·17 (0·49 to 3·91)
1·47 (0·90 to 2·25) 
1·95 (1·30 to 2·74) 
2·11 (1·49 to 3·15) 
2·03 (1·03 to 4·74) 
2·38 (1·25 to 3·90) 
2·50 (1·21 to 4·34)
2·58 (1·30 to 4·30)
2·73 (2·00 to 3·98)
2·54 (1·15 to 7·35)
3·16 (2·02 to 4·56)
4·41 (0·89 to 8·94)
3·57 (1·52 to 6·29)
3·76 (2·99 to 4·61)
3·93 (2·70 to 5·38)
4·83 (2·22 to 13·33) 
4·95 (1·91 to 18·18) 
5·26 (2·07 to 8·69)
6·18 (1·66 to 10·49)
 9·43 (2·16 to 13·19) 
12·16 (1·47 to 14·44) 
23·81 (7·41 to 142·86) 
15·04 (1·68 to 15·04)
CLO (n=11)
PERA (n=35)
SER (n=714)
ILO (n=303)
OLA (n=2956)
PBO (n=5091)
QUE (n=1720)
BRE (n=1200)
ZOT (n=184)
PAL (n=844)
ARI (n=1116)
ZIP (n=1360)
THIOR (n=194)
ASE (n=578)
AMI (n=271)
CPZ (n=567)
RIS (n=2104)
THIOT (n=134)
CAR (n=1029)
PERPH (n=83)
LOX (n=170)
HAL (n=3246)
LUR (n=1385)
TRIFLU (n=133)
SUL (n=110)
MOL (n=88)
PEN (n=83)
PIM (n=24)
FLU (n=10)
ZUC (n=26)
FPX (n=13)
–0·16 (–0·73 to 0·40)
0·00 (0·00 to 0·00)
0·32 (–0·22 to 0·87)
0·48 (–0·05 to 1·01)
0·54 (0·15 to 0·95)
0·70 (–0·05 to 1·45)
0·73 (–0·06 to 1·52)
0·66 (–1·51 to 2·85)
0·84 (0·14 to 1·53)
0·53 (–5·54 to 6·71)
1·01 (–0·49 to 2·55) 
1·02 (–0·31 to 2·36) 
0·56 (–13·14 to 14·21) 
1·09 (–2·44 to 4·64) 
1·21 (0·47 to 1·93) 
2·04 (–8·17 to 12·67) 
1·57 (–1·58 to 4·74) 
1·44 (1·05 to 1·83) 
2·32 (–11·27 to 15·7) 
1·49 (0·98 to 2·00)
1·89 (0·36 to 3·43) 
1·94 (1·42 to 2·45) 
2·18 (1·47 to 2·89) 
2·37 (1·43 to 3·32) 
2·47 (1·68 to 3·26) 
2·78 (2·44 to 3·13) 
3·21 (2·10 to 4·31)
ZIP (n=1266)
PBO (n=5722)
LUR (n=1253)
ARI (n=1199)
HAL (n=2586)
BRE (n=1113)
CAR (n=874)
CPX (n=20)
AMI (n=592)
ZUC (n=61)
FPX (n=75)
PERA (n=75)
MOL (n=44)
LOX (n=17)
ASE (n=727)
SUL (n=41)
LEV (n=32)
RIS (n=2521)
TRIFLU (n=36)
PAL (n=1536)
CLO (n=113)
QUE (n=2143)
ILO (n=936)
CPZ (n=308)
SER (n=643)
OLA (n=4198)
ZOT (n=186)
MD (95% CrI)
A Weight gain in kg (N=116 [29%], n=28317 [53%])
RR (95% CrI)
C Akathisia (NT=116 [29%], nT=25783 [48%])
Favours antipsychotic Favours placebo
1050 15
Favours antipsychotic Favours placebo
0–100 50–50
Favours antipsychotic Favours placebo
0 2 4
–77·05 (–120·23 to –33·54)*
–42·23 (–82·42 to –1·78)*
–7·10 (–11·17 to –3·09)
–10·45 (–38·75 to 18·22)
–13·44 (–50·27 to 23·64)
–3·19 (–9·21 to 2·80)
–1·17 (–4·52 to 2·27)
0·00 (0·00 to 0·00)
0·95 (–3·64 to 5·62)
–3·91 (–89·56 to 82·66) 
2·75 (–2·14 to 7·66)
4·47 (1·60 to 7·38)
4·79 (–1·05 to 10·66)
5·05 (0·01 to 10·14)
8·70 (–8·16 to 25·75)
7·04 (3·03 to 11·05)
10·12 (4·52 to 15·63)
18·49 (15·60 to 21·39)
26·87 (15·63 to 38·19)
37·98 (34·64 to 41·38)
48·51 (43·52 to 53·51)
CLO (n=24)
ZOT (n=48)
ARI (n=1076)
FPX (n=41)
PERA (n=34)
CAR (n=859)
QUE (n=1997)
PBO (n=4985)
BRE (n=1070)
PIM (n=6)
ZIP (n=1046)
OLA (n=2411)
ILO (n=451)
ASE (n=886)
CPZ (n=90)
LUR (n=1192)
SER (n=466)
HAL (n=2001)
AMI (n=58)
RIS (n=1761)
PAL (n=1067)
0·46 (0·19 to 0·88) 
0·74 (0·22 to 1·61) 
0·92 (0·64 to 1·41)
1·00 (1·00 to 1·00)
1·02 (0·79 to 1·30)
1·05 (0·78 to 1·48) 
1·21 (0·66 to 1·91) 
1·45 (0·23 to 3·25)
1·32 (0·90 to 1·82)
1·16 (0·58 to 3·09)
1·46 (0·96 to 2·04)
1·53 (0·69 to 2·63)
1·60 (0·80 to 2·63)
1·61 (1·17 to 2·10)
1·70 (1·23 to 2·46)
1·80 (1·40 to 2·38)
1·94 (1·42 to 2·48) 
2·02 (1·18 to 3·94) 
2·21 (1·18 to 3·37) 
2·17 (1·48 to 2·91) 
2·38 (1·07 to 7·35) 
2·64 (1·32 to 3·92) 
3·02 (1·14 to 4·66)
3·06 (1·60 to 6·90)
3·10 (1·54 to 7·75) 
3·21 (1·52 to 4·66) 
3·48 (1·31 to 5·12) 
3·13 (1·99 to 4·16)
3·99 (1·27 to 5·65) 
3·12 (2·74 to 3·50) 
5·99 (2·42 to 21·74) 
4·61 (2·55 to 5·74) 
6·14 (4·81 to 6·55)
CLO (n=144) 
PERA (n=73) 
SER (n=819)
PBO (n=4584) 
OLA (n=3012) 
QUE (n=2224)
ASE (n=280) 
LEV (n=21)
ARI (n=678) 
THIOR (n=160) 
AMI (n=517) 
ILO (n=303)
BRE (n=598) 
PAL (n=1355) 
ZIP (n=928) 
RIS (n=2174) 
LUR (n=1385)
ZOT (n=228)
CAR (n=279) 
CPZ (n=557)
SUL (n=78)
PERPH (n=101)
MOL (n=101)
ZUC (n=106) 
TRIFLU (n=193)
FPX (n=75)
PEN (n=29)
LOX (n=203)
FLU (n=25)
HAL (n=3549) 
THIOT (n=48)
CPX (n=40) 
PIM (n=44)
RR (95% CrI)
B Use of antiparkinson medication (NT=136 [34%], nT=24911 [47%])
MD (95% CrI)
D Prolactin elevation in ng/mL (NT=90 [22%], nT=21569 [40%])
Favours antipsychotic Favours placebo
2·50 7·5 10·05·0
(Figure 4 continues on next page)
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High Moderate Low Very low
1·00 (1·00 to 1·00)
0·92 (0·17 to 2·03) 
1·11 (0·59 to 1·69) 
1·09 (0·31 to 2·09) 
1·12 (0·70 to 1·59) 
1·20 (0·41 to 2·13) 
1·24 (0·53 to 2·04) 
1·33 (1·00 to 1·68) 
1·36 (0·84 to 1·93) 
1·40 (0·65 to 2·20) 
1·38 (0·98 to 2·07) 
1·46 (1·11 to 1·83) 
1·56 (0·91 to 2·23) 
1·53 (0·93 to 3·00)
1·64 (0·91 to 2·38) 
1·75 (1·38 to 2·11) 
2·03 (1·67 to 2·51)
1·96 (0·90 to 2·89) 
1·92 (1·68 to 2·15) 
2·63 (1·66 to 4·61) 
2·17 (1·59 to 2·68) 
2·20 (1·65 to 2·73) 
2·17 (1·93 to 2·40)
2·72 (1·63 to 5·29) 
2·91 (2·27 to 3·89) 
3·27 (2·61 to 4·22) 
2·96 (1·16 to 3·78) 
2·55 (2·16 to 2·90) 
4·08 (2·04 to 10·10) 
5·35 (3·12 to 10·31) 
3·16 (2·09 to 3·73) 
3·02 (2·52 to 3·37) 
10·20 (4·72 to 29·41)
PBO (n=6280) 
PIM (n=30)
PERPH (n=151)
FLU (n=30)
CAR (n=566)
LEV (n=53)
PEN (n=83)
PAL (n=1248)
ILO (n=303)
MOL (n=77)
SER (n=800)
ARI (n=935)
AMI (n=314)
TRIFLU (n=177)
BRE (n=972)
LUR (n=1385)
RIS (n=2824)
FPX (n=75)
HAL (n=3318) 
THIOR (n=198)
ASE (n=751)
LOX (n=337)
OLA (n=3730) 
THIOT (n=148)
ZIP (n=1360) 
QUE (n=2726) 
PERA (n=20) 
CPZ (n=1078) 
SUL (n=110) 
ZOT (n=233) 
CPX (n=35) 
CLO (n=347) 
ZUC (n=76)
–2·21 (–4·54 to 0·15)
–1·46 (–4·71 to 1·81)
–1·45 (–6·20 to 3·20)
–0·43 (–3·62 to 2·77)
0·00 (0·00 to 0·00)
1·21 (–2·89 to 5·31) 
1·69 (–0·23 to 3·64) 
3·43 (0·94 to 6·00)
4·29 (1·91 to 6·68) 
4·77 (2·68 to 6·87) 
5·60 (–0·94 to 12·00)
6·93 (4·49 to 9·36) 
9·70 (7·43 to 12·04) 
14·10 (7·71 to 20·45) 
23·90 (20·56 to 27·33)
LUR (n=1131)
BRE (n=695)
CAR (n=438)
ARI (n=603)
PBO (n=2875)
PAL (n=222)
HAL (n=1788)
QUE (n=1114)
OLA (n=1895)
RIS (n=1295)
ASE (n=57)
ILO (n=869)
ZIP (n=1701)
AMI (n=110)
SER (n=674)
MD (95% CrI)
E  QTc prolongation in ms (NT=51 [13%], nT=15467 [29%])
RR (95% CrI)
F Sedation (NT=162 [40%], nT=30770 [58%])
Favours antipsychotic Favours placebo
0 302010 5·02·5 10·00·0 7·5
Favours antipsychotic Favours placebo
12·5
0·72 (0·31 to 1·38) 
0·90 (0·24 to 2·19) 
1·00 (1·00 to 1·00)
1·11 (0·53 to 1·92) 
1·14 (0·68 to 1·76) 
1·17 (0·40 to 2·49)
1·21 (0·34 to 2·75) 
1·01 (0·47 to 2·86) 
1·32 (0·58 to 2·48)
1·30 (0·83 to 1·90) 
1·31 (1·03 to 1·72) 
1·33 (0·96 to 1·97) 
1·27 (0·64 to 3·01) 
1·42 (0·84 to 2·20)
1·35 (0·84 to 2·38) 
1·45 (0·84 to 2·29) 
1·63 (0·51 to 3·56) 
1·53 (0·75 to 2·66) 
1·36 (0·62 to 4·00)
2·14 (0·21 to 5·71) 
1·50 (1·14 to 1·93) 
2·13 (0·62 to 4·53) 
1·94 (1·46 to 2·48) 
2·23 (0·97 to 3·95) 
5·39 (0·24 to 10·73) 
2·21 (1·26 to 3·47) 
2·80 (1·14 to 5·13) 
3·32 (0·98 to 6·53) 
2·58 (1·74 to 3·60) 
2·67 (1·29 to 6·58) 
2·73 (0·81 to 23·26) 
3·53 (1·97 to 7·25) 
3·89 (2·83 to 5·56)
BRE (n=468)
MOL (n=42)
PBO (n=5516)
ASE (n=531)
LUR (n=1013)
PIM (n=44)
LEV (n=53)
SUL (n=110)
PERPH (n=184)
ARI (n=964)
RIS (n=3084)
ZIP (n=1360)
THIOT (n=155)
PAL (n=764)
SER (n=518) 
CAR (n=717)
PEN (n=68) 
AMI (n=452) 
TRIFLU (n=94) 
FLU (n=20) 
HAL (n=2744) 
FPX (n=75) 
OLA (n=3166)
LOX (n=173) 
PERA (n=20) 
CLO (n=302)
ILO (n=303) 
CPX (n=45) 
CPZ (n=858) 
ZOT (n=219) 
ZUC (n=26) 
THIOR (n=198) 
QUE (n=2618)
G At least one anticholinergic side-effect (NT=134 [33%], nT=26904 [50%])
5·02·5 10·00·0 7·5
Favours antipsychotic Favours placebo
RR (95% CrI)
Figure 4: Change in 
side-effect outcomes
(A) Weight gain in kg. 
(B) Use of antiparkinson 
medication. (C) Akathisia. 
(D) Prolactin elevation in 
ng/mL. (E) QTc prolongation in 
ms. (F) Sedation. (G) At least 
one anticholinergic side-effect. 
Treatments are ranked 
according to their surface 
under the curve cumulative 
ranking and compared with 
placebo. Effect sizes are 
presented as mean difference 
or risk ratio with 95% CrIs. 
The evidence is graded using 
CINeMA system (Confidence in 
Network Meta-Analysis), 
an adaption of the GRADE 
(Grading of Recommendations, 
Assessment, Development, 
and Evaluations) approach for 
network meta-analysis. 
Colours indicate the confidence 
in the evidence: green=high, 
blue=moderate, grey=low, 
red=very low. NT=total number 
of trials reporting the outcome 
(percentage of sample). 
nT=total number of participants 
available for the respective 
outcome (percentage of 
sample). MD=Mean difference. 
CrI=credible interval. 
RR=risk ratio. AMI=amisulpride. 
ARI=aripiprazole. 
ASE=asenapine. 
BRE=brexpiprazole. 
CAR=cariprazine. 
CLO=clozapine. 
CPX=clopenthixol. 
CPZ=chlorpromazine. 
FLU=fluphenazine. 
FPX=flupentixol. 
HAL=haloperidol. 
ILO=iloperidone. 
LEV=levomepromazine. 
LOX=loxapine. LUR=lurasidone. 
MOL=molindone. 
OLA=olanzapine. 
PAL=paliperidone. 
PBO=placebo. PEN=penfluridol. 
PERA=perazine. 
PERPH=perphenazine. 
PIM=pimozide. 
QUE=quetiapine. 
RIS=risperidone. 
SER=sertindole. SUL=sulpiride. 
THIOR=thioridazine. 
THIOT=thiotixene. 
TRIFLU=trifluoperazine. 
ZIP=ziprasidone. 
ZOT=zotepine. 
ZUC=zuclopenthixol. *Results 
for clozapine and zotepine 
might be statistical artifacts 
caused by two small outlier 
studies.
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examining discontinuation due to inefficacy we found 
comparable results as for the primary outcome overall 
change in symptoms (appendix p 279).
116 studies (29%) with 28 317 (53%) participants 
presented usable results for weight gain. 12 (46%) of 
26 antipsychotics caused significantly more weight 
gain than placebo with mean differences ranging from 
0·54 kg (95% CrI 0·15–0·95) for haloperidol to 3·21 kg 
(2·10–4·31) for zotepine (figure 4A). Zotepine, olanzapine, 
and sertindole produced significantly more weight gain 
than most other drugs (appendix pp 200–21). The 
hierarchy for patients with at least 7% weight gain was 
similar, confirming the findings (appendix p 280).
136 studies (34%) with 24 911 (47%) participants 
reported use of antiparkinson medication. Risk ratios 
for the 21 (66%) of 32 antipsychotics that were associated 
with significantly increased use of anti parkinson 
medication compared with placebo ranged from 1·61 
(95% CrI 1·17–2·10) for paliperidone to 6·14 (4·81–6·55) 
for pimozide (figure 4B). The following drugs were 
significantly better than haloperidol starting with 
the best: clozapine, perazine, sertindole, placebo, 
olanzapine, quetiapine, asenapine, aripiprazole, thiori-
dazine, amisul pride, iloperidone, brexpiprazole, pali-
peridone, zipra sidone, risperidone, lurasidone, zotepine, 
and chlor promazine (appendix pp 200–21). 116 studies 
(29%) with 25 783 (48%) participants reported results for 
akathisia. The hierarchy was similar to use of anti-
parkinson medication, with significant risk ratios for 
20 (67%) of 30 drugs ranging from 1·95 (95% CrI 
1·30–2·74) for aripiprazole to 23·81 (7·41–142·86) for 
zuclopenthixol (figure 4C).
90 studies (22%) with 21 569 participants (40%) 
reported usable results for prolactin. Olanzapine, asen-
apine, lurasidone, sertindole, haloperidol, amisulpride, 
risperidone, and paliperidone were associated with 
significantly elevated prolactin levels (mean difference 
range 4·47–48·51 ng/mL). For many antipsychotics (eg, 
sulpiride) prolactin data were not available (figure 4D).
51 studies (13%) with 15 467 participants (29%) reported 
usable data for QTc prolongation. Seven (50%) of 14 anti-
psychotics caused significantly more QTc prolongation 
than placebo with mean differences ranging from 3·43 ms 
(95% CrI 0·94–6·00) for quetiapine to 23·90 ms (95% CrI 
20·56–27·33) for sertindole (figure 4E).
162 studies (40%) with 30 770 participants (58%) reported 
results for sedation (32 antipsychotics). Risk ratios for 
the 18 drugs (56%) that were significantly more sedating 
than placebo ranged from 1·33 (95% CrI 1·00–1·68) 
for paliperidone to 10·20 (95% CrI 4·72–29·41) for 
zuclopenthixol, and there was some evidence of sedation 
for most of the remaining antipsychotics (figure 4F).
134 studies (33%) with 26 904 participants (50%) 
reported anticholinergic side-effects (32 antipsychotics). 
This outcome can be affected by use of anticholinergic 
medication, which is often needed for the treatment of 
extrapyramidal side-effects. Evidence for significantly 
higher risk than placebo was present for risperidone, 
haloperidol, olanzapine, clozapine, iloperidone, chlor-
promazine, zotepine, thioridazine, and quetiapine (risk 
ratio range 1·31–3·89; figure 4G).
Heterogeneity was low to moderate for most 
outcomes, moderate to high for use of antiparkinson 
medication, and high for prolactin elevation. SIDE 
testing showed that the percentage of com parisons with 
evidence of inconsistency was 2–26% for all outcomes, 
except for quality of life with 50% comparisons 
with evidence of inconsistency; therefore, this outcome 
was examined in a pairwise meta-analysis (appendix 
p 222). Additionally, prolactin results were significantly 
incon sistent according to the design-by-treatment 
interaction test. Because prolactin values vary widely 
between men and women and assays used in different 
laboratories, we also applied SMDs, and heterogeneity 
and inconsistency were sub stantially lower (appendix 
pp 223, 224, 281).
The most important differences in terms of study 
characteristics were that older antipsychotics had less 
placebo response than newer ones and that the anti-
psychotics differed in their median baseline severity 
across studies (appendix pp 53–61). These potential 
threats to the transitivity assumption and other potential 
effect modi fiers were addressed by metaregressions and 
sensitivity analyses of the primary outcome, excluding 
antipsychotics studied in less than 100 participants. The 
degree of placebo response, which has increased in the 
past 60 years,27 had the greatest effect on heterogeneity. 
The effect sizes of the individual antipsychotics changed 
after accounting for response to placebo, but the overall 
hierarchy did not (appendix pp 177–89). This finding was 
corroborated by removing placebo groups or placebo-
controlled studies in sensitivity analyses (appendix 
pp 190–99). Publication year, mean participants’ age, 
baseline severity, percentage of male patients, sample 
size, and sponsoring also did not affect the hierarchy of 
relative treatment effects compared with the unadjusted 
analysis (appendix pp 177–89). Sensitivity analyses 
removing studies with overall high risk of bias, completer 
analyses, imputed standard deviations, duration more 
than six weeks, and unfair dose comparisons, failed 
trials, and trials done before 1990 did not affect the 
results (appendix pp 190–99).
The certainty of the evidence was low overall (appendix 
p 242). Concerning the primary outcome, we judged the 
confi dence in the evidence for 75% of the comparisons 
with placebo to be low or very low (figure 2A), and this was 
the case for 92% of the comparisons of two antipsychotic 
drugs (appendix p 242). Many older antipsychotics are 
among those with poor CINeMA ratings and often have 
no evidence for several secondary outcomes.
Comparison of the change in overall symptoms of 
all antipsychotics with haloperidol by use of a contour-
enhanced funnel plot did not reveal any asymmetry and 
the SMD did not change using the trim-and-fill method 
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(appendix p 285). By contrast, comparison of all anti-
psychotics with placebo revealed that smaller trials 
exaggerate the effectiveness of the active interventions 
versus placebo. SMD changed from 0·45 to 0·38, 
confirming an earlier analysis.27
Discussion
To our knowledge, this analysis is the largest network 
meta-analysis in the field of schizophrenia, based on 
402 studies including 53 463 participants randomly 
assigned to 32 different first-generation and second-
generation antipsychotics or placebo. We extended our 
previous report3 by two second-generation antipsychotics 
and 15 first-generation antipsychotics and by investigating 
ten additional important outcomes, including specific 
aspects of efficacy, quality of life, and many more side-
effects, and several methodological issues, including 
placebo response and sample sizes.3
Individual effect size estimates suggest that all anti-
psychotic drugs reduced overall symptoms more than 
placebo (not significant for six drugs) with mean effect 
sizes between –0·89 and –0·03 (median –0·42). However, 
overlapping CrIs between antipsychotics suggest that 
differences between most individual drugs were not 
significant. With few exceptions, only clozapine, 
amisulpride, zotepine, olanzapine, and risperidone were 
significantly more efficacious for the primary outcome 
than other antipsy chotics. Readers should consult figure 3, 
which provides these comparisons. Amisulpride was 
among the most efficacious anti psychotics, but no 
placebo-controlled study was available, making this 
evidence entirely indirect. Nevertheless, amisulpride was 
significantly superior to placebo in older patients 
(≥60 years of age; SMD 0·86) and in patients with 
predominant negative symptoms (SMD 0·47).28,29
Mainly newer antipsychotics provided data separately 
for positive and negative symptoms, but they were similar 
to data for overall change in symptoms. However, all 
included studies focused on positive symptoms, because 
studies with predominant negative symptoms were 
excluded in this analysis and were evaluated separately.28 
Whether differences in negative symptoms relate to 
primary or just secondary negative symptoms is 
impossible to clarify in populations with positive 
symptoms. The fact that many drugs improved depressive 
symptoms more than placebo might also reflects a 
reduction of anxiety and distress associated with 
schizophrenia. Nevertheless, aripiprazole, brexpiprazole, 
cariprazine, lurasidone, and quetiapine are licensed in 
several countries for major depression, bipolar 
depression, or both. So is flupentixol, but we did not find 
an antidepressant effect for it on the basis of sparse data 
(62 participants).30 Many antipsychotics did not have data 
for quality of life, an important outcome for patients 
because it combines efficacy and safety. If reported, most 
drugs showed better effects than placebo. Some but not 
all drugs also outperformed placebo in terms of social 
functioning in these short-term studies, an outcome 
associated with recovery and social reintegration.
Because all-cause discontinuation combines efficacy 
and tolerability, it has been used as a measure of 
effectiveness in the CATIE trial.31 When reported 
separately, more patients dropped out due to inefficacy 
(40%) than due to adverse events (20%) in the included 
trials so that all-cause discontinuation is primarily an 
efficacy measure.
Antipsychotics are often taken for a long period, so side-
effects have an important role concerning morbidity and 
adherence and might affect cognition.32 Antipsychotics 
very often scored worse than placebo for side-effect 
outcomes, with different profiles. In general, older anti-
psychotics were associated often with more extrapyra-
midal motor side-effects and prolactin elevation (with 
noticeable exceptions, such as amisulpride, paliperidone, 
and risperi done), whereas many newer antipsychotics 
produced more weight gain and sedation. We consider 
weight gain to be a good proxy for metabolic side-effects in 
this already dense review.33 Specific metabolic side-effects 
such as glucose, insulin, homeostatic model assessment 
for insulin resistance, total cholesterol, LDL cholesterol, 
HDL cholesterol, and triglycerides will be addressed in 
future reviews. In contrast to our previous report, we 
present QTc prolongation in original units (ms), which 
facilitates clinical interpretation; lurasidone and the partial 
dopamine agonists were the most benign drugs.
With regard to efficacy and safety outcomes many older 
antipsychotics, limited by few direct comparisons, per-
formed well compared with newer antipsychotics. This 
finding is important, because in low-income and middle-
income countries, second-generation antipsychotics might 
not be affordable. However, older studies with negative 
results could have remained unpublished more frequently, 
whereas now all clinical trials should be registered. In an 
analysis of all antipsychotics compared with placebo, 
contour-enhanced funnel plots suggested the existence of 
unpublished studies.
Our analysis had limitations. We used strict inclusion 
criteria to obtain a homogenous sample, nevertheless 
the included studies were done over a 60-year period, 
during which study characteristics changed. Checking for 
consistency revealed few inconsistent loops and low-to-
moderate heterogeneity in most outcomes (appendix 
pp 223, 224), but the overall power to detect inconsistency 
is low.16 Major exceptions were quality of life, for which a 
network meta-analysis was not calculated, and prolactin 
increase. Because prolactin results might depend on the 
laboratory assay used, we calculated SMDs in addition to 
mean differences (appendix p 281), which reduced 
heterogeneity strongly. Still, the finding that clozapine and 
zotepine significantly reduced prolactin compared with 
placebo (with wide CrIs) might be a statistical artifact 
driven by outliers, because only two small trials were 
available. The most important threat to the transitivity 
assumption of network meta-analysis was the increase of 
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placebo response over the years,27,34 because adjusting for 
placebo response in a metaregression strongly reduced 
heterogeneity (τ) by 60–63% (appendix pp 179–83). In this 
metaregression model, the ranking was not substantially 
different from the primary analysis. Additionally, removing 
placebo groups, placebo-controlled studies, and failed 
studies in sensitivity analyses did not substantially change 
the results nor did metaregressions of six other moderators 
and further sensitivity analyses, supporting the robustness 
of the findings. The results of the network meta-analysis 
were consistent overall with those of pairwise meta-
analyses (figure 3) and single studies. For example, a study 
comparing brexpiprazole with placebo and quetiapine 
found that brexpiprazole was better than placebo, but 
worse than quetiapine, similar to the hierarchy of our 
analysis.35 In a long-term study (sponsored by asenapine’s 
manufacturer) olanzapine was significantly better than 
asenapine.36 Thus, we do not believe that placebo response 
explains all efficacy differences between the compounds. 
Nevertheless, the statistical methods could not fully 
account for the heterogeneity,27 so some efficacy differences 
might appear larger than they actually are.
Our decision to exclude studies from mainland China 
reduces the generalisability of the results to this country. 
However, a literature and telephone interview study 
suggested that most Chinese trials continue to be of low 
quality.14 Chinese reports are usually very short and 
communication with the authors is often difficult due to 
language barriers, thus risk of bias is difficult to assess. 
Therefore, we a-priori decided to exclude Chinese studies.
Clinical trials exclude suicidal patients, and the severely 
ill are unlikely to be included in modern trials because 
providing informed consent is often not possible for 
them. With a mean duration of illness of 12 years, our 
sample consisted mainly of chronic patients, who are 
known to respond worse compared with first-episode 
patients.37 These factors reduce generalisability.
For feasibility reasons our risk of bias assessment 
focused on the primary outcome; however, risk of bias is 
outcome-specific (appendix pp 273–77). Moreover, the 
evidence for many secondary outcomes (eg, social 
functioning) was based on much lower sample sizes 
compared with the primary outcome (4370 vs 40 815).
These limitations reduced the strength of the derivable 
recommendations, particularly (but not only) for older 
antipsychotics, because their effect sizes are based 
primarily on one or two studies with sample sizes smaller 
than 100. Small sample sizes leave room for small 
trial effects, which might have inflated some results. 
For example, the large effect of clozapine concerning 
reduction of negative symptoms is based on 159 partici-
pants, because clozapine is mainly studied in treatment-
resistant patients who were excluded from the analysis. 
The contribution of direct evidence is small for older 
drugs, resulting in wide CrIs, higher uncertainty, and 
lower confidence in the evidence evaluated by CINeMA. 
The generally smaller amounts of data available for old 
drugs, except for perphenazine, which had more 
evidence of good quality from a large trial,31 are 
highlighted in the figures and should be considered in 
the interpretation of all findings.
Because so many antipsychotic options are available, 
our results should help health-care providers find the 
most suitable drug for the individual patient, balancing 
side-effect profiles and the efficacy of different drugs. We 
confirm that antipsychotics differ more in their side-
effects than in their efficacy. We believe that efficacy 
differences between compounds exist, but the fact that 
their measurement is based on subjective rating scales is 
problematic. The development of objective efficacy 
measures would render interpretation easier. Clinicians 
must remember that reported results are averages and 
that response and side-effects might vary considerably in 
individual patients.
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